Heme Oxygenase-1 in Liver Surgery
Not Applicable
Completed
- Conditions
- iver surgery/pharmacological preconditioningSurgeryLiver surgery
- Registration Number
- ISRCTN94278797
- Lead Sponsor
- niversity of Edinburgh (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
1. Patients scheduled to undergo major hepatic resection (three or more segments)
2. Aged between 18 and 80 years, either sex
Exclusion Criteria
1. Patients undergoing minor resections (less than three segments)
2. Jaundiced patients (bilirubin greater than 100 µmol/l)
3. Patients with established cirrhosis
4. Patients who have had a previous liver resection
5. Patients who are unable to give informed consent
6. Patients who are pregnant or breastfeeding
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Heme oxygenase-1 induction will be measured in the resected liver specimen, and also in peripheral blood cells. HO-1 levels will be assessed by laboratory mesasurement of HO-1 messenger ribonucleic acid (mRNA) and protein level (real-time polymerase chain reaction [PCR] and Western blotting respectively) and HO enzymatic activity. HO-1 will be localised in the liver by immunohistochemistry of the liver tissue. Total body production of carbon monoxide (CO, a product of HO-1 activity) will be measured by CO levels in exhaled air and by blood levels of carboxy-haemoglobin.
- Secondary Outcome Measures
Name Time Method iver function on each day during the hospital stay will be assessed by clinical and biochemical means. Clnical evidence of encephalopathy and clinical progress will be measured. Serum levels of alanin aminotransferase (ALT), prothrombin time (PT), lactate and bilirubin will be measured biochemically. Hepatic clearance of indocyanine green will be measured.